The jumpstart model reduces drug development risk by starting with existing drugs which are then reformulated or repurposed for new or expanded indications. In every case, the parent drug either already belongs to somebody else or has lost patent protection, or soon will, and is therefore freely available for others to exploit. As such, early competition is a significant risk for any jumpstart product. Devising an IP fence high enough to protect a new product could determine a company's success going forward.
by Marc Wortman
In March, a British court struck down GlaxoSmithKline PLC 's composition-of-matter patent for its most important new drug, the anti-asthma inhaler Seretide (sold as Advair in the US)—a combination...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
